RXDX-105 (CEP-32496)
Agerafenib, also known as RXDX-105, CEP-32496 and AC013773, is an orally available v-raf murine sarcoma viral oncogene homolog B1 (B-raf) serine/threonine protein kinase inhibitor with potential antineoplastic activity. CEP-32496 specifically and selectively inhibits the activity of the mutated form (V600E) of B-raf kinase. This inhibits the activation of the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway and may result in a decrease in the proliferation of tumor cells expressing the mutated B-raf gene.
Supplier | Alfa Cytology |
---|---|
Product # | BC0565 |
Pricing | 10.0 mg, 25.0 mg, 50.0 mg, 100.0 mg, 200.0 mg, 500.0 mg, 1.0 g, inquire |